<p>根據 MarketBeat.com 的報道，阿博維公司（NYSE:ABBV - 獲取免費報告）的股票獲得了 26 位分析師的共識推薦為 “適度買入”。七位分析師給予該股票持有評級，十六位給予買入評級，三位給予強烈買入評級。在過去一年中，對該股票發佈評級的經紀商的平均 12 個月目標價為 210.71 美元。</p>
<ul>
<li>3 只生物製藥股票逆勢而上</li>
</ul>
<p>幾家研究公司對阿博維進行了評論。Erste Group Bank 在 3 月 17 日的研究報告中將阿博維的股票評級上調至 “強烈買入”。摩根士丹利在 4 月 11 日的研究報告中重申了對阿博維股票的 “持有” 評級。瑞銀集團在 2 月 3 日的研究報告中將阿博維的目標價從 181.00 美元上調至 190.00 美元，並給予該股票 “中性” 評級。富國銀行在 3 月 5 日的報告中將阿博維的目標價從 210.00 美元上調至 240.00 美元，並給予公司 “增持” 評級。最後，花旗集團在 2 月 3 日的報告中將阿博維的目標價從 205.00 美元上調至 215.00 美元，並給予公司 “買入” 評級。</p>
<p><strong>獲取我們最新的阿博維股票報告</strong></p>
<h2>阿博維股票表現</h2>
<ul>
<li>MarketBeat 周度回顧 – 03/24 - 03/28</li>
</ul>
<p>阿博維股票在週二開盤價為 170.01 美元。該公司的市值為 3007.4 億美元，市盈率為 70.84，市盈增長比率為 1.62，貝塔值為 0.55。阿博維的 12 個月最低價為 153.58 美元，最高價為 218.66 美元。該公司的 50 日移動平均價格為 198.01 美元，200 日移動平均價格為 187.54 美元。公司的債務與股本比率為 17.94，流動比率為 0.66，速動比率為 0.55。</p>
<p>阿博維（NYSE:ABBV - 獲取免費報告）最近一次發佈季度財報是在 1 月 31 日。該公司報告的每股收益（EPS）為 2.16 美元，低於分析師的共識預期 2.98 美元，差額為 0.82 美元。阿博維的淨利潤率為 7.59%，股本回報率為 296.28%。去年同期，該公司每股收益為 2.79 美元。研究分析師預計阿博維今年的每股收益將達到 12.31 美元。</p>
<h2>阿博維宣佈分紅</h2>
<ul>
<li>阿博維股票通過進入減肥市場提升投資組合</li>
</ul>
<p>該公司最近宣佈了一項季度分紅，將於 5 月 15 日支付。4 月 15 日的股東將獲得 1.64 美元的分紅。這代表着每年 6.56 美元的分紅和 3.86% 的收益率。該分紅的除息日為 4 月 15 日。阿博維的分紅支付比率（DPR）目前為 273.33%。</p>
<h2>阿博維的內部交易</h2>
<p>在相關消息中，執行副總裁 Perry C. Siatis 在 2 月 20 日的交易中出售了 5,778 股公司的股票。股票以平均價格 197.90 美元出售，總價值為 1,143,466.20 美元。出售完成後，該執行副總裁現在直接持有 22,381 股公司股票，價值為 4,429,199.90 美元。此次交易使其持股減少了 20.52%。該出售在向 SEC 的文件中披露，相關信息可在 SEC 網站上找到。此外，執行副總裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股公司的股票。股票以平均價格 202.90 美元出售，總價值為 6,070,159.30 美元。交易完成後，該執行副總裁現在持有 44,284 股公司股票，價值為 8,985,223.60 美元。此次交易使其持股減少了 40.32%。該出售的披露信息可以在此找到。過去 90 天內，內部人士出售了 113,471 股公司股票，價值為 23,426,451 美元。內部人士持有該股票的比例為 0.25%。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Fiduciary Advisors Inc.在第四季度購買了阿博維的新股份，價值約為 29,000 美元。EnRich Financial Partners LLC 在第四季度將其在阿博維的持股增加了 196.4%。EnRich Financial Partners LLC 現在擁有 166 股公司股票，價值 29,000 美元，此前在上個季度增持了 110 股。Promus Capital LLC 在第四季度購買了阿博維的新股份，價值 30,000 美元。Bradley &amp; Co. Private Wealth Management LLC 在第四季度購買了阿博維的新股份，價值約為 31,000 美元。最後，Prudent Man Investment Management Inc.在第四季度購買了阿博維的新股份，價值約為 32,000 美元。目前，70.23% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於阿博維</h2>
<p>（獲取免費報告）</p>
<p>阿博維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；以及 Venclexta/Venclyxto 用於治療血癌。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票超過阿博維</li>
<li>股票情緒分析：如何運作</li>
<li>AST SpaceMobile：購買這隻小型開拓者股票的五個理由</li>
<li>萬億美元市值的意義超越數字</li>
<li>為什麼看漲期權交易者現在瞄準這隻分紅 ETF</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>Alphabet 被誤解了嗎？這就是為什麼看漲者正在購買</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
<p>在考慮艾伯維之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而艾伯維並不在名單上。</p>
<p>雖然艾伯維目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

艾伯維

<p>艾伯維（AbbVie Inc.，紐約證券交易所代碼：ABBV）獲得了 26 位分析師的 “適度買入” 共識推薦。12 個月的平均目標價為 210.71 美元，其中 16 位分析師建議買入，3 位建議強烈買入。最近的評級包括 Erste Group Bank 的 “強烈買入” 以及富國銀行將目標價上調至 240 美元。艾伯維上個季度報告的每股收益為 2.16 美元，未達到預期，並宣佈季度股息為 1.64 美元。內部交易顯示高管進行了大量股票出售</p>

<p>Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the twenty-six analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation, sixteen have given a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $210.71.</p>
<div class="lb-trans"><p>根據 MarketBeat.com 的報道，阿博維公司（NYSE:ABBV - 獲取免費報告）的股票獲得了 26 位分析師的共識推薦為 “適度買入”。七位分析師給予該股票持有評級，十六位給予買入評級，三位給予強烈買入評級。在過去一年中，對該股票發佈評級的經紀商的平均 12 個月目標價為 210.71 美元。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物製藥股票逆勢而上</li>
</ul>
</div><p>Several research firms have commented on ABBV. Erste Group Bank raised shares of AbbVie to a &#34;strong-buy&#34; rating in a research note on Monday, March 17th. Morgan Stanley reaffirmed a &#34;hold&#34; rating on shares of AbbVie in a research note on Friday, April 11th. UBS Group raised their price objective on shares of AbbVie from $181.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, February 3rd. Wells Fargo &amp; Company boosted their price target on shares of AbbVie from $210.00 to $240.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, March 5th. Finally, Citigroup raised their target price on AbbVie from $205.00 to $215.00 and gave the company a &#34;buy&#34; rating in a report on Monday, February 3rd.</p>
<div class="lb-trans"><p>幾家研究公司對阿博維進行了評論。Erste Group Bank 在 3 月 17 日的研究報告中將阿博維的股票評級上調至 “強烈買入”。摩根士丹利在 4 月 11 日的研究報告中重申了對阿博維股票的 “持有” 評級。瑞銀集團在 2 月 3 日的研究報告中將阿博維的目標價從 181.00 美元上調至 190.00 美元，並給予該股票 “中性” 評級。富國銀行在 3 月 5 日的報告中將阿博維的目標價從 210.00 美元上調至 240.00 美元，並給予公司 “增持” 評級。最後，花旗集團在 2 月 3 日的報告中將阿博維的目標價從 205.00 美元上調至 215.00 美元，並給予公司 “買入” 評級。</p>
</div><p><strong>Get Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的阿博維股票報告</strong></p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>阿博維股票表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 03/24 - 03/28</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周度回顧 – 03/24 - 03/28</li>
</ul>
</div><p>AbbVie stock opened at $170.01 on Tuesday. The company has a market cap of $300.74 billion, a PE ratio of 70.84, a P/E/G ratio of 1.62 and a beta of 0.55. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66. The company has a fifty day moving average price of $198.01 and a two-hundred day moving average price of $187.54. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55.</p>
<div class="lb-trans"><p>阿博維股票在週二開盤價為 170.01 美元。該公司的市值為 3007.4 億美元，市盈率為 70.84，市盈增長比率為 1.62，貝塔值為 0.55。阿博維的 12 個月最低價為 153.58 美元，最高價為 218.66 美元。該公司的 50 日移動平均價格為 198.01 美元，200 日移動平均價格為 187.54 美元。公司的債務與股本比率為 17.94，流動比率為 0.66，速動比率為 0.55。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period last year, the business posted $2.79 EPS. Research analysts expect that AbbVie will post 12.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿博維（NYSE:ABBV - 獲取免費報告）最近一次發佈季度財報是在 1 月 31 日。該公司報告的每股收益（EPS）為 2.16 美元，低於分析師的共識預期 2.98 美元，差額為 0.82 美元。阿博維的淨利潤率為 7.59%，股本回報率為 296.28%。去年同期，該公司每股收益為 2.79 美元。研究分析師預計阿博維今年的每股收益將達到 12.31 美元。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>阿博維宣佈分紅</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>阿博維股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.86%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 273.33%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項季度分紅，將於 5 月 15 日支付。4 月 15 日的股東將獲得 1.64 美元的分紅。這代表着每年 6.56 美元的分紅和 3.86% 的收益率。該分紅的除息日為 4 月 15 日。阿博維的分紅支付比率（DPR）目前為 273.33%。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>阿博維的內部交易</h2>
</div><p>In related news, EVP Perry C. Siatis sold 5,778 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the sale, the executive vice president now directly owns 22,381 shares of the company's stock, valued at $4,429,199.90. The trade was a 20.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy J. Richmond sold 29,917 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the completion of the transaction, the executive vice president now owns 44,284 shares in the company, valued at $8,985,223.60. The trade was a 40.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock worth $23,426,451 over the last ninety days. 0.25% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Perry C. Siatis 在 2 月 20 日的交易中出售了 5,778 股公司的股票。股票以平均價格 197.90 美元出售，總價值為 1,143,466.20 美元。出售完成後，該執行副總裁現在直接持有 22,381 股公司股票，價值為 4,429,199.90 美元。此次交易使其持股減少了 20.52%。該出售在向 SEC 的文件中披露，相關信息可在 SEC 網站上找到。此外，執行副總裁 Timothy J. Richmond 在 2 月 26 日的交易中出售了 29,917 股公司的股票。股票以平均價格 202.90 美元出售，總價值為 6,070,159.30 美元。交易完成後，該執行副總裁現在持有 44,284 股公司股票，價值為 8,985,223.60 美元。此次交易使其持股減少了 40.32%。該出售的披露信息可以在此找到。過去 90 天內，內部人士出售了 113,471 股公司股票，價值為 23,426,451 美元。內部人士持有該股票的比例為 0.25%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fiduciary Advisors Inc. bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $29,000. EnRich Financial Partners LLC lifted its holdings in shares of AbbVie by 196.4% during the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. Promus Capital LLC purchased a new position in AbbVie in the fourth quarter worth $30,000. Bradley &amp; Co. Private Wealth Management LLC purchased a new stake in AbbVie during the fourth quarter valued at about $31,000. Finally, Prudent Man Investment Management Inc. bought a new stake in AbbVie during the fourth quarter worth about $32,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了對該股票的持股。Fiduciary Advisors Inc.在第四季度購買了阿博維的新股份，價值約為 29,000 美元。EnRich Financial Partners LLC 在第四季度將其在阿博維的持股增加了 196.4%。EnRich Financial Partners LLC 現在擁有 166 股公司股票，價值 29,000 美元，此前在上個季度增持了 110 股。Promus Capital LLC 在第四季度購買了阿博維的新股份，價值 30,000 美元。Bradley &amp; Co. Private Wealth Management LLC 在第四季度購買了阿博維的新股份，價值約為 31,000 美元。最後，Prudent Man Investment Management Inc.在第四季度購買了阿博維的新股份，價值約為 32,000 美元。目前，70.23% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About AbbVie</h2>
<div class="lb-trans"><h2>關於阿博維</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>阿博維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；以及 Venclexta/Venclyxto 用於治療血癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Why Call Option Traders Are Targeting This Dividend ETF Now</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過阿博維</li>
<li>股票情緒分析：如何運作</li>
<li>AST SpaceMobile：購買這隻小型開拓者股票的五個理由</li>
<li>萬億美元市值的意義超越數字</li>
<li>為什麼看漲期權交易者現在瞄準這隻分紅 ETF</li>
<li>ESG 股票，投資者應瞭解的事項</li>
<li>Alphabet 被誤解了嗎？這就是為什麼看漲者正在購買</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮艾伯維之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而艾伯維並不在名單上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然艾伯維目前在分析師中獲得了中性買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

艾伯維公司（NYSE: ABBV）被券商平均推薦為 “適度買入”